1.02Open0.91Pre Close20 Volume661 Open Interest8.00Strike Price2.09KTurnover51.60%IV2.37%PremiumDec 20, 2024Expiry Date0.86Intrinsic Value100Multiplier18DDays to Expiry0.21Extrinsic Value100Contract SizeAmericanOptions Type0.8311Delta0.2456Gamma9.09Leverage Ratio-0.0078Theta0.0032Rho7.55Eff Leverage0.0050Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet